Monday, 14 October 2024

New Home for the BioLargo Blog - www.biolargo.com/blog

As of October 14, 2024, there's a new home for the BioLargo blog:

https://www.biolargo.com/blog.

The old blog (where you are now) will be kept online as a historical archive for all posts older than Oct 14, 2024.

Enjoy the new and better reading experience on the new site!

- Alex Evans, Director of Corporate Communications

Wednesday, 18 September 2024

BioLargo Engineering's Battery Event Highlighted in Local News

An NBC affiliate in Knoxville covered the story of our ribbon-cutting ceremony today - watch for yourself below!

Monday, 16 September 2024

BioLargo to Host Ribbon-Cutting Event for Battery Pilot Manufacturing Facility

Westminster, CA – September 16, 2024 – BioLargo, Inc. (OTCQX:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, announced that it will be hosting a ribbon-cutting ceremony to showcase its pilot-scale manufacturing facility for its CellinityTM next-generation battery energy storage technology. The invite-only event will take place on September 21, 2024, at BioLargo’s engineering headquarters and manufacturing facilities in Oak Ridge, Tennessee.

Cellinity is BioLargo’s next-generation battery platform designed to provide safe, environmentally conscious large-format long-duration battery energy storage for applications including grid-scale storage, renewable energy storage, charging stations for electric vehicles, and a variety of other commercial and industrial applications. The company will give a tour of the company’s manufacturing facility as well as presentations about how Cellinity batteries could improve and empower renewable energy storage and grid reliability in Tennessee and anywhere hoping to rely on renewable energy. The company will also present a new prototype scaled-up version of its Cellinity battery cells.

According to BioLargo President and CEO Dennis P. Calvert, “We are excited to share more information about Cellinity at this event, including showcasing the design of our larger Cellinity cell that will be used in commercial Cellinity battery systems. While much work is left to be done before the facility is producing finished, commercial-grade batteries, we’re excited to celebrate the impressive progress our engineers have made toward that goal.”

He continued, “We are also thrilled to host our potential international partners from Norway, where we hope to advance our business model to ‘sell factories, not batteries’. Much like North America, Northern Europe has made tremendous headway in developing renewable energy projects, but just like in America, safe and affordable battery energy storage systems are crucial to empowering the transition to green energy in Europe. We have a number of projects in development.”

Learn more about Cellinity at www.BioLargoEnergy.com.

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com. 

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Monday, 9 September 2024

Clyra Medical Technologies, a Subsidiary of BioLargo, Appoints Dr. Steven J. Kavros as Chief Medical Officer

WESTMINSTER, CA / ACCESSWIRE / September 9, 2024 / BioLargo, Inc. (OTCQX:BLGO), a developer of sustainable environmental and life sciences technologies, announced that its partially owned subsidiary Clyra Medical Technologies had appointed Dr. Steven J. Kavros as its new Chief Medical Officer.

Dr. Kavros brings a wealth of medical expertise and experience in advanced wound healing and limb preservation to his new role at Clyra. He spent over 20 years at the prestigious Mayo Clinic in Rochester, MN, where he served as Director at the Gonda Vascular Wound Healing Center, and was involved in both research and patient care. He was also deeply engaged in medical education as Associate Professor at the Mayo Clinic's Alix School of Medicine.

Dr. Kavros is also an accomplished researcher and speaker, having given over 1,800 presentations related to his research activities at national and international conferences, and lead author of numerous peer-reviewed papers centered on new medical technologies and evidence-based medicine.

In addition to his clinical and academic achievements, Dr. Kavros has a proven track record in the medical device industry, successfully bringing to market multiple products in advanced wound healing, limb preservation, and orthopedics. He has also served in leadership roles at EPIEN Medical, TEI Biosciences, Miromatrix Medical, and Innovacyn.

Dr. Kavros earned a bachelor's degree in Biology with honors and a minor in Chemistry from Rutgers University and subsequently graduated from Temple University School of Podiatric Medicine with highest honors in surgery, orthopedics, biomechanics and podiatric medicine. Dr. Kavros is also a certified wound specialist through the American Board of Wound Management, a fellow of the American College of Certified Wound Specialists, and a founding member of the American Professional Wound Care Association, where he also served as scientific chair and later as its president from 2015-2019.

Clyra CEO Steve Harrison commented "Dr. Kavros' unique blend of clinical expertise and business insight will prove invaluable to support our significant investments for at-scale manufacturing and distribution of our Bioclynse product. His skills in leadership, team building, and entrepreneurship align perfectly with Clyra's vision and goals."


About Clyra Medical Technologies, Inc.

Clyra Medical Technologies, founded on our mission of "Make Lives Better", is a healthcare company that develops and commercializes products designed to safely treat wound and skin infections and promote wound healing, while reducing the need for antibiotics.

Clyra Medical Technologies is a proud member of the BioLargo Family of Companies (www.biolargo.com). Clyra is a subsidiary of BioLargo, Inc., a publicly traded company, with the stock symbol (OTCQX:BLGO) BioLargo is a technology innovator and solutions provider focused on some of the world's most pressing human health and environmental challenges including advanced water treatment, environmental remediation, air quality control, medical technologies, and more.

About BioLargo, Inc.

BioLargo, Inc. (OTCQX: BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

dennis.calvert@biolargo.com

888-400-2863

Tuesday, 13 August 2024

BioLargo Earnings Results Webcast and Conference Call on Wednesday, August 14, 2024 - 1:30 PM Pacific Time

WESTMINSTER, CA / ACCESSWIRE / August 13, 2024 / BioLargo, Inc. (OTCQX:BLGO), a developer of sustainable technologies and full-service environmental engineering company, announced it will host an investor webcast and conference call on Wednesday, August 14, 2024 at 1:30 pm Pacific Time / 4:30 pm Eastern Time. The event, which will be open to the public, will be held to review the company's financial results for the three months and six months ended June 30, 2024, discuss recent milestones, and conduct a question-and-answer session.

To listen to a live broadcast, go to the site linked below at least 15 minutes prior to the scheduled start time to register and download any necessary audio/video software.

To participate in the live webcast and teleconference:


Webcast Link: https://www.webcaster4.com/Webcast/Page/2448/51101
Teleconference Domestic: 877-545-0523
Teleconference International: 973-528-0016
Participant Access Code: 739107


To watch or listen to a replay of the webcast or teleconference:


Teleconference Replay Expiration: August 28, 2024
Webcast Replay Expiration: November 14, 2024
Teleconference Replay Domestic: 877-481-4010
Teleconference Replay International: 919-882-2331
Replay Passcode: 51101


The webcast replay and accompanying presentation materials will be made available on the Investor Relations section of BioLargo's website at www.biolargo.com/investor-relations.


About BioLargo, Inc.

BioLargo, Inc. (OTCQX:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com.


Contact Information

Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863


Safe Harbor Act

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") anticipated revenue and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.


Contact Information

Dennis Calvert
President and CEO
dennis.calvert@biolargo.com
(949) 235-8062


SOURCE: BioLargo, Inc.

Tuesday, 6 August 2024

BioLargo Achieves Record Quarterly Revenue of $5 Million for Second Quarter of 2024

Q2 2024 revenues grew 247% compared to same three months last year

Westminster, CA – August 6, 2024 – BioLargo, Inc. (OTCQX:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, announced preliminary results for its second quarter ended June 30, 2024:

  • Companywide revenue ($5.0 million) for the quarter increased 247% compared with the second quarter of 2023 and increased 5% compared to the first quarter of 2024 (revenues for the six months ended June 30, 2024, increased 88% over the first six months of 2023).
  • The company had a net loss for the quarter of $780,000, which included approximately $540,000 in non-cash stock option compensation expense.  
  • At June 30, 2024, the company had $4.8 million in cash and cash equivalents, and $10.1 million total assets.
  • The company’s total stockholder’s equity increased to $5.9 million as of June 30, 2024.

BioLargo’s President and CEO Dennis P. Calvert said of the results, “We had another quarter of record revenues, and we continue to strengthen our balance sheet. We are in a strong position to continue advancing the commercialization of our multiple cleantech products and services.”

The company is still working to finalize its quarterly report on Form 10-Q for the period ended June 30, 2024, which it intends to file on or before the August 14, 2024 deadline. The revenue estimates described here are preliminary and subject to change pending the review process.

The company plans to hold an earnings conference call and webcast on August 14, 2024, to discuss its results, and will provide more information about this event soon.

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com. 

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Monday, 8 July 2024

New Study Confirms Forever Chemicals Are Absorbed Through Human Skin


A new study on widespread “forever chemicals” by the University of Birmingham published in Environment International proved for the first time that a wide range of PFAS chemicals can be readily absorbed through human skin. Although the chemicals are already well known to enter the body through other means such as ingestion (eating and drinking) and inhalation, it has until recently been thought that PFAS are unable to breach the skin barrier. The new study, however, confirms that most of them can enter the body via this route.  

Dr. Oddny Ragnarsdóttir, the lead author of the study, stated: “The ability of these chemicals to be absorbed through skin has previously been dismissed because the molecules are ionized. The electrical charge that gives them the ability to repel water and stains was thought to also make them incapable of crossing the skin membrane”. The research instead shows that this theory does not always hold, and significant amounts of PFAS exposure can be a result of absorption through the skin.  

Among the thousands of different types of PFAS, the researchers chose 17 of the most widely used and studied, and those that directly corresponded to chemicals specifically regulated by the EU’s Drinking Water Directive. Of the 17 tested PFAS, 15 showed substantial absorption of at least 5% of the exposure dose. The study also showed that absorption correlated with carbon chain length, with longer chain molecules absorbing less than shorter chain molecules. This study provides much needed evidence of how skin contact and carbon chain length can affect exposure and raises several questions at a time when industry is shifting towards shorter chain PFAS believing them to be less toxic.